Guggenheimanalyst Vamil Divan maintains $Travere Therapeutic(TVTX.US)$ with a buy rating, and maintains the target price at ...

Join Us at the Blue Hope Bash to Support the Fight Against Colorectal Cancer / Blue Hope Bash Committee, cancer, colorectal ...

Pharmaceutical & Biotech Stock Introductory Series, Part 2, Episode 1 / 12 Episodes Total]IntroductionLigand Pharmaceuticals ...

In late September and early October 2026, Travere Therapeutics reported new FILSPARI® (sparsentan) data across IgA ...

(Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the ...

This is a real growth story, and FILSPARI is now the only approved medicine in its younger indication. But I rate the shares a Hold at this price. The valuation has run ahead of the evidence: roughly ...

New grant program supporting innovations in early detection and accurate diagnosis of kidney failure to be announced at summit ...

Travere Therapeutics (Nasdaq: TVTX) plans to present nine data sets, including five oral presentations, on its drug Filspari (sparsentan) at the American Society of Nephrology Kidney Week 2026 in ...

Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation are on Capitol Hill with more than 80 advocates who are living with rare kidney diseases to urge elected officials to support ...

Summary:The company released its 2026 interim report, reporting revenue of RMB 1.148 billion for the first half of 2026, up ...